These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 29993319

  • 21. Reducing the risk of obesity: defining the role of weight loss drugs.
    Ling H, Lenz TL, Burns TL, Hilleman DE.
    Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
    [Abstract] [Full Text] [Related]

  • 22. Weight loss strategies for treatment of obesity.
    Kushner RF.
    Prog Cardiovasc Dis; 2014 Dec; 56(4):465-72. PubMed ID: 24438739
    [Abstract] [Full Text] [Related]

  • 23. Bariatric surgery - time to replace with GLP-1?
    Webb DL, Abrahamsson N, Sundbom M, Hellström PM.
    Scand J Gastroenterol; 2017 Dec; 52(6-7):635-640. PubMed ID: 28276830
    [Abstract] [Full Text] [Related]

  • 24. Approaches to obesity management.
    Sweeting AN, Caterson ID.
    Intern Med J; 2017 Jul; 47(7):734-739. PubMed ID: 28677316
    [Abstract] [Full Text] [Related]

  • 25. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D, Prasad-Reddy L, Srivastava SB.
    Am J Health Syst Pharm; 2016 Oct 01; 73(19):1493-507. PubMed ID: 27521241
    [Abstract] [Full Text] [Related]

  • 26. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW, Torekov SS, Holst JJ.
    Expert Opin Pharmacother; 2014 Dec 01; 15(17):2487-500. PubMed ID: 25260877
    [Abstract] [Full Text] [Related]

  • 27. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.
    Meek CL, Lewis HB, Reimann F, Gribble FM, Park AJ.
    Peptides; 2016 Mar 01; 77():28-37. PubMed ID: 26344355
    [Abstract] [Full Text] [Related]

  • 28. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, Henriksen K.
    Am J Physiol Endocrinol Metab; 2017 Nov 01; 313(5):E598-E607. PubMed ID: 28292761
    [Abstract] [Full Text] [Related]

  • 29. Pharmacotherapy in Conjunction with a Diet and Exercise Program for the Treatment of Weight Recidivism or Weight Loss Plateau Post-bariatric Surgery: a Retrospective Review.
    Schwartz J, Chaudhry UI, Suzo A, Durkin N, Wehr AM, Foreman KS, Tychonievich K, Mikami DJ, Needleman BJ, Noria SF.
    Obes Surg; 2016 Feb 01; 26(2):452-8. PubMed ID: 26615406
    [Abstract] [Full Text] [Related]

  • 30. [Efficacy and future of endoscopic bariatric surgery in the treatment of obesity and metabolic diseases].
    Huang S, Zhang J, Dong Z, Wang C.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr 25; 20(4):383-387. PubMed ID: 28440517
    [Abstract] [Full Text] [Related]

  • 31. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1.
    Osto E, Doytcheva P, Corteville C, Bueter M, Dörig C, Stivala S, Buhmann H, Colin S, Rohrer L, Hasballa R, Tailleux A, Wolfrum C, Tona F, Manz J, Vetter D, Spliethoff K, Vanhoutte PM, Landmesser U, Pattou F, Staels B, Matter CM, Lutz TA, Lüscher TF.
    Circulation; 2015 Mar 10; 131(10):871-81. PubMed ID: 25673670
    [Abstract] [Full Text] [Related]

  • 32. Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study.
    Naude J, Zentner A, Suresh P, Bittman J, Khan NA.
    Int J Obes (Lond); 2024 Aug 10; 48(8):1118-1125. PubMed ID: 38724682
    [Abstract] [Full Text] [Related]

  • 33. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.
    Bojsen-Møller KN.
    Dan Med J; 2015 Apr 10; 62(4):B5057. PubMed ID: 25872541
    [Abstract] [Full Text] [Related]

  • 34. [Recent progress and novel perspectives on obesity pharmacotherapy].
    Faria AM, Mancini MC, Melo ME, Cercato C, Halpern A.
    Arq Bras Endocrinol Metabol; 2010 Aug 10; 54(6):516-29. PubMed ID: 20857056
    [Abstract] [Full Text] [Related]

  • 35. An Introduction to Current State of Obesity Interventions: A Guide for the Interventional Radiologist.
    Weiss CR.
    Tech Vasc Interv Radiol; 2020 Mar 10; 23(1):100652. PubMed ID: 32192632
    [No Abstract] [Full Text] [Related]

  • 36. Treatment of obesity in 2015.
    Shukla AP, Buniak WI, Aronne LJ.
    J Cardiopulm Rehabil Prev; 2015 Mar 10; 35(2):81-92. PubMed ID: 25714749
    [Abstract] [Full Text] [Related]

  • 37. Recent concepts of pharmacotherapy and bariatric surgery for childhood obesity: an overview.
    Gogakos A, Tzotzas TC, Krassas GE.
    Pediatr Endocrinol Rev; 2009 Dec 10; 7(2):3-14. PubMed ID: 20118889
    [Abstract] [Full Text] [Related]

  • 38. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M, Troskot R.
    Minerva Endocrinol; 2015 Mar 10; 40(1):71-83. PubMed ID: 25366984
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic advances in obesity management: an overview of the therapeutic interventions.
    Roomy MA, Hussain K, Behbehani HM, Abu-Farha J, Al-Harris R, Ambi AM, Abdalla MA, Al-Mulla F, Abu-Farha M, Abubaker J.
    Front Endocrinol (Lausanne); 2024 Mar 10; 15():1364503. PubMed ID: 38715796
    [Abstract] [Full Text] [Related]

  • 40. Weight Regain After Bariatric Surgery: Prevalence, Etiology, and Treatment.
    Velapati SR, Shah M, Kuchkuntla AR, Abu-Dayyeh B, Grothe K, Hurt RT, Mundi MS.
    Curr Nutr Rep; 2018 Dec 10; 7(4):329-334. PubMed ID: 30168043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.